SavedAdd your journal

Journals / Erciyes Medical Journal / 2021 / Cilt: 43 - Sayı: 5

Characterization of Cancer Immune Landscape in Primary Central Nervous System Lymphoma

Deniz PEKER
Kai WANG
Fei FEİ
Pages
487–493
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PCNSL has a poor prognosis, with a median overall survival of 30–50 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal variant of non-Hodgkinlymphomas with disease confined to the brain, spinal cord, leptomeninges, or orbit, without evidence of systemic involve ment.
📊
Key Findings & Data:PCNSL has a poor prognosis, with a median overall survival of 30–50 months.
💡
Conclusion & Impact:We identified four genes with deregulated expressions (adjusted p
🔬Design:Research Article
📍Scope:2005 · 12 samples
⚙️Variables:Domain Parameters

Abstract

Objective: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal variant of non-Hodgkinlymphomas with disease confined to the brain, spinal cord, leptomeninges, or orbit, without evidence of systemic involve ment. PCNSL has a poor prognosis, with a median overall survival of 30–50 months. We used NanoString Technologies tocharacterize the cancer immune profiles in PCNSL and associated the findings with clinical outcome. Materials and Methods: A total of 33 patients between 2005 and 2017 were included in our study, and clinical informa tion was collected. A PanCancer IO 360 panel (NanoString Technologies) was used to assess the expression level of 770genes related to tumor immunity in 12 samples. We also investigated the programmed death ligand 1 (PD-L1) expressionand T-cell infiltrate in 25 PCNSL samples using immunohistochemistry. Results: NanoString analysis showed that gene expressions differed between human immunodeficiency virus (HIV)-positiveand HIV-negative PCNSL. We identified four genes with deregulated expressions (adjusted p

🔖

Cite This Article

PEKER, D., WANG, K., FEİ, F. (2022). Characterization of Cancer Immune Landscape in Primary Central Nervous System Lymphoma. Erciyes Medical Journal, Cilt: 43 - Sayı: 5, 487–493. https://ajindex.com/articles/502241

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Schaff LR, Grommes C. Updates on primary central nervous system lymphoma. Curr Oncol Rep 2018; 20(2): 11
  2. Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 2017; 129(23): 3071–3
  3. Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol 2016; 18(9): 1297–303
  4. Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 2013; 9(6): 317–27
  5. Illerhaus G, Schorb E, Kasenda B. Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood 2018; 132(7): 681–8
  6. Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget 2017; 8(2): 2171–86
  7. Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 2017; 14(4): 203–20
  8. Liu J, Quan L, Zhang C, Liu A, Tong D, Wang J. Over-activated PD-1/ PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen. Oncol Lett 2018; 15(3): 3321–8
  9. Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 2016; 127(7): 869–81
  10. Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014; 14(8): 517–34
  11. Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica 2019; 104(2): 338–46
  12. Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, et al. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunother Cancer 2019; 7(1): 139. Erratum in: J Immunother Cancer 2019; 7(1): 273
  13. Wang K, Shen T, Siegal GP, Wei S. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Hum Pathol 2017; 69: 110–7
  14. Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lym